Arcutis Biotherapeutics, Inc.

Trading Plans

On September 1, 2026, Patrick Burnett, our Chief Medical Officer, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Between December 2, 2026 and August 31, 2027, the plan provides for the potential exercise and sale of up to 100,000 options, the potential sale of up to 38,150 shares resulting from the vesting of RSUs and the potential sale of up to 20,117 shares of common stock held by Mr. Burnett.

Chief Commercial Officer

On October 31, 2026, our board of directors appointed Robert Lisicki, who has served as the Company's interim executive vice president and interim chief commercial officer since August 2026, as the Company's executive vice president and chief commercial officer on a permanent basis, effective as of November 4, 2026. Mr.

Lisicki's appointment as interim executive vice president and interim chief commercial officer, his biographical information, and the material terms of his compensatory arrangements with the Company were previously reported in Item 5.02 of the Company's Current Report on Form 8-K filed with the SEC on August 5, 2026 (Prior Form 8-K), which information is incorporated herein by reference. Other than the change in Mr. Lisicki's role from interim to permanent basis, there have been no changes to the information reported in the Prior Form 8-K, including the terms of his Employment Agreement and Severance & Change in Control Agreement (each as defined in the Prior Form 8-K). Each of those agreements is filed as an exhibit to this Quarterly Report on Form 10-Q.

Employment and Severance Agreements

Our board of directors approved certain updates to our severance and change in control agreements with our executive officers. The updated agreements increase the severance paid in the form of continued base salary and annual bonus and extend the duration of COBRA reimbursements. In the event of a qualifying termination (i) within eighteen (18) months following a change of control or (ii) within three (3) months preceding a change in control, (a) Mr. Todd Franklin Watanabe will be entitled to receive severance pay in an amount equal to twenty-four (24) months of his base salary rate in effect immediately prior to the qualifying termination, 2.0 times his annual bonus amount for the then-current fiscal year based on 100% of target performance, and twenty-four (24) months of COBRA reimbursements, and (b) our other executive officers will be entitled to receive severance pay in an amount equal to eighteen (18) months of their base salary rate in effect immediately prior to the qualifying termination, 1.5 times their annual bonus amount for the then-current fiscal year based on 100% of target performance, and eighteen (18) months of COBRA reimbursements, in each case paid out in a single cash lump sum. We have entered or will enter into updated severance and change in control agreements with our executive officers.